As a research-led healthcare company, we strive to develop medicines where there is high unmet clinical need.

Flagship Research

Wintermute has multiple therapeutic compounds in its development pipeline. Wintermute compounds demonstrate exceptional potential for the treatment of infections. Some key advantages of include:


High levels of potency, providing rapid eradication of infectious organisms.

Excellent safety

High levels of safety captured during in-vitro and in-vivo testing.

Broad spectrum

Activity against gram-positive and gram-negative bacteria, fungi and viruses.

Combats resistance

Zero evidence of resistance development during standardized testing.

Long lasting

Ongoing protection against infections.

Environmentally Friendly

With no harmful chemicals and water-based.


Wintermute compounds have demonstrated efficacy for a wide range of organisms; most of which make up the CDC’s Biggest Threats list

Infectious Organisms

  • ‍Carbapenem-resistant Enterobacteriaceae (CRE)
  • ‍Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBLs)
  • ‍Multidrug-resistant Pseudomonas aeruginosa
  • ‍Methicillin-resistant Staphylococcus aureus (MRSA)
  • ‍Drug-resistant Streptococcus pneumoniae
  • ‍Vancomycin-resistant Staphylococcus aureus (VRSA)
  • ‍Drug-resistant Streptococcus (Groups A and B)
  • ‍MCR-1 (E. coli)
  • Mycobacterium Ulcerans
  • Plus many more!

Flagship Development

Wintermute compounds are currently being developed for treating skin infections and wounds, including those caused by Methicillin-resistant Staphylococcus aureus MRSA and other drug-resistant bacteria. Skin infections are among the most common diseases worldwide, placing an immense burden on global healthcare. In 2010, skin infection ranked 4th among all diseases for years lost due to disability (YLD). It is estimated that up to 70% of all people will suffer one or more skin diseases during their lifetime. The micro-organism responsible for the majority of skin infections is Staphylococcus aureus, of which over 60% are MRSA strains (known as “golden staph”).

Research Areas

At Wintermute Biomedical, we are performing leading-edge research and development into the discovery of next-generation therapeutics and consumer products to prevent and combat infectious diseases. In addition to progressing Wintermute compounds for treating skin infections, we are actively researching, developing and testing:

Antibacterials, anti-virals and anti-fungals.

Systemic therapeutics, including for the treatment of respiratory disease and blood stream infections.

Medical device coatings for infection control.


Wintermute compounds are in pre-clinical development, and are anticipated to enter clinical trials soon.

Our Promise

Our team won’t rest until Wintermute compounds are available to the many patients who desperately need it.